ArticleInvestigational new drugs2022
Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.
Jing-Jing Wu et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
24 papers cite it
this papertrialcites it